Maximum acceptable decrease in the probability of achieving clear or almost clear skin at week 16
| Attribute/level | Maximum acceptable decrease in the probability of achieving clear or almost clear skin (95% CI) |
| Itch reduction | |
| 2 out of 10 (20%) | Reference |
| 4 out of 10 (40%) | 38.7 (28.8 to 48.6) |
| 5 out of 10 (50%) | 50.1 (38.5 to 61.8) |
| Eye inflammation | |
| 20 out of 100 (20%) | Reference |
| 10 out of 100 (10%) | 17.9 (10.5 to 25.4) |
| 0 out of 100 (0%) | 42.3 (30.0 to 54.5) |
| Serious infections | |
| 6 out of 100 (6%) | Reference |
| 3 out of 100 (3%) | 20.6 (12.7 to 28.6) |
| 0 out of 100 (0%) | 48.6 (35.2 to 62.0) |
| Speed of onset | |
| 2 weeks | Reference |
| 1 week | 0.2 (−6.5 to 6.9) |
| 2 days | 11.3 (4.4 to 18.2) |
| Flare management | |
| No | Reference |
| Yes | 5.8 (0.5 to 11.1) |
| Long-term disease management | |
| Yes, without the possibility for pauses | Reference |
| Should not be used long-term | 4.3 (−2.7 to 11.3) |
| Yes, with the possibility for pauses | 24.1 (16.5 to 31.6) |
| Administration | |
| Injection under the skin every 2 weeks | Reference |
| Oral pill one time or two times per day | 16.6 (9.2 to 24.0) |
| Check-ups | |
| Frequent check-ups required | Reference |
| Occasional check-ups required | 16.1 (8.7 to 23.5) |
| No check-ups required | 20.9 (12.3 to 29.5) |